Inhibikase Therapeutics Inc (IKT) Stock Price, Quote & News

Company Profile

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to im...

Industry: Biotechnology

Sector: Healthcare

Phone: 302 295 3800

Website: www.inhibikase.com

Address:

1000 N. West Street, Suite 1200, Wilmington, United States

Mjf04288 Aug. 11 at 8:16 PM

$IKT https://www.inhibikase.com/news/press-releases/detail/145/inhibikase-therapeutics-announces-second-quarter-2026

0 · Reply

BiotechJedi1728 Aug. 5 at 11:02 AM

$IKT

0 · Reply

BiotechJedi1728 Aug. 4 at 8:04 PM

$IKT This is how we do it!

0 · Reply

Mjf04288 Jul. 28 at 10:48 PM

$IKT It looks like Black Rock increased their position

0 · Reply

freddieg24 Jul. 28 at 3:00 PM

$IKT if this hits the low end of a price target before earnings this could happen a lot sooner than everyone thinks watch closely up until the 14th for any pull backs but this is gaining some good support and traction…. who knows whats on the 2026 horizon… we definitely wont get any trial results until early/mid next year (stating the obvious) but this is everything a bullish biotech stock needs

0 · Reply

PepsiLover Jul. 27 at 3:11 PM

$IKT This stock is so stable even with routine P&D every few months lol, really wish this one gonna work out next year.

0 · Reply

Avocado_smash Jul. 27 at 12:37 PM

$IKT PT 2.68++

0 · Reply

LSOTradingDesk Jul. 26 at 9:13 AM

$IKT Worth watching for RSI to actually turn up through 40 before treating this as an entry zone — right now it's still in the falling phase of the pullback.

0 · Reply

BiotechJedi1728 Jul. 24 at 9:28 PM

$IKT Whoever sold 60,000 shares at 2.40 will be regretting that Monday.

1 · Reply

Goodguy22 Jul. 24 at 8:40 PM

Bought $IKT shares at 2.37

0 · Reply

Inhibikase Therapeutics reports Q2 EPS (11c), consensus (9c)

2026-07-23T12:16:10.000Z - 19 days ago

Inhibikase Therapeutics IKT-001 gets Orphan Drug Designation from FDA

Jul 23, 2026, 8:00 AM EDT - 19 days ago

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

2026-07-16T21:05:22.000Z - 26 days ago

Inhibikase Therapeutics’ treatment of PAH granted FDA orphan designation

Jul 14, 2026, 8:00 AM EDT - 4 weeks ago

Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility

Jul 2, 2026, 4:01 PM EDT - 5 weeks ago

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-06-10T11:34:59.000Z - 2 months ago

Inhibikase Therapeutics initiated with an Outperform at Oppenheimer

May 12, 2026, 4:01 PM EDT - 3 months ago

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

May 12, 2026, 4:00 PM EDT - 3 months ago

Inhibikase Therapeutics Earnings release: Q1 2026

May 12, 2026, 4:00 PM EDT - 3 months ago

Inhibikase Therapeutics Quarterly report: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Inhibikase Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Inhibikase Therapeutics Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Inhibikase Therapeutics Proxy statement: Proxy filing

2026-04-07T12:42:54.000Z - 4 months ago

Inhibikase Therapeutics enrolls first patient in IMPROVE-PAH study

Apr 7, 2026, 8:00 AM EDT - 4 months ago

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

Apr 1, 2026, 7:00 AM EDT - 4 months ago

Inhibikase Therapeutics Slides: Corporate presentation

Mar 26, 2026, 4:01 PM EDT - 4 months ago

Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

Mar 26, 2026, 4:00 PM EDT - 4 months ago

Inhibikase Therapeutics Annual report: Q4 2025

Mar 26, 2026, 4:00 PM EDT - 4 months ago

Inhibikase Therapeutics Earnings release: Q4 2025

2026-03-04T12:41:55.000Z - 5 months ago

Inhibikase Therapeutics initiated with a Buy at Ladenburg

2026-03-04T11:48:05.000Z - 5 months ago

Inhibikase Therapeutics initiated with a Buy at Ladenburg

2026-01-21T11:31:15.000Z - 7 months ago

Inhibikase Therapeutics initiated with a Buy at BofA

2025-12-11T13:00:48.000Z - 8 months ago

Inhibikase Therapeutics initiated with an Overweight at Cantor Fitzgerald

2025-11-21T04:00:11.000Z - 9 months ago

Inhibikase Therapeutics 46.1M share Spot Secondary priced at $1.45

Nov 20, 2025, 9:54 PM EST - 9 months ago

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

2025-11-20T21:50:22.000Z - 9 months ago

Inhibikase Therapeutics TBA Spot Secondary; reoffered at $1.45

2025-11-20T21:15:17.000Z - 9 months ago

Inhibikase announces common stock and warrants offering, no amount given

Nov 20, 2025, 4:12 PM EST - 9 months ago

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

2025-11-20T21:11:51.000Z - 9 months ago

Inhibikase Therapeutics to advance IKT-001 to Phase 3 clinical study in PAH

Nov 20, 2025, 4:01 PM EST - 9 months ago

Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension

Nov 20, 2025, 6:00 AM EST - 9 months ago

Inhibikase Therapeutics Slides: Corporate presentation

Nov 14, 2025, 4:01 PM EST - 9 months ago

Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity

Nov 14, 2025, 4:00 PM EST - 9 months ago

Inhibikase Therapeutics Quarterly report: Q3 2025

Nov 14, 2025, 4:00 PM EST - 9 months ago

Inhibikase Therapeutics Earnings release: Q3 2025

2025-08-19T12:15:43.000Z - 1 year ago

Inhibikase Therapeutics appoints Pigot as Chief Commercial, Strategy Officer

Aug 19, 2025, 8:00 AM EDT - 1 year ago

Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

Aug 14, 2025, 4:50 PM EDT - 1 year ago

Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

Aug 14, 2025, 4:00 PM EDT - 1 year ago

Inhibikase Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 1 year ago

Inhibikase Therapeutics Earnings release: Q2 2025

2025-06-20T21:10:07.000Z - 1 year ago

Inhibikase Therapeutics files $300M mixed securities shelf

Jun 20, 2025, 8:00 AM EDT - 1 year ago

Inhibikase Therapeutics Registration statement: Registration Filing

Jun 12, 2025, 8:00 AM EDT - 1 year ago

Inhibikase Therapeutics Proxy statement: Proxy Filing

May 14, 2025, 4:05 PM EDT - 1 year ago

Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

May 14, 2025, 9:30 AM EDT - 1 year ago

Inhibikase Therapeutics Quarterly report: Q1 2025

May 14, 2025, 9:30 AM EDT - 1 year ago

Inhibikase Therapeutics Earnings release: Q1 2025

May 12, 2025, 8:00 AM EDT - 1 year ago

Inhibikase Therapeutics Proxy statement: Proxy Filing

May 12, 2025, 8:00 AM EDT - 1 year ago

Inhibikase Therapeutics Proxy statement: Proxy Filing

May 2, 2025, 8:00 AM EDT - 1 year ago

Inhibikase Therapeutics Proxy statement: Proxy Filing

2025-04-14T12:15:44.000Z - 1 year ago

Inhibikase Therapeutics announces appointment of McIntyre as CFO

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

Mjf04288 Aug. 11 at 8:16 PM

$IKT https://www.inhibikase.com/news/press-releases/detail/145/inhibikase-therapeutics-announces-second-quarter-2026

0 · Reply

BiotechJedi1728 Aug. 5 at 11:02 AM

$IKT

0 · Reply

BiotechJedi1728 Aug. 4 at 8:04 PM

$IKT This is how we do it!

0 · Reply

Mjf04288 Jul. 28 at 10:48 PM

$IKT It looks like Black Rock increased their position

0 · Reply

freddieg24 Jul. 28 at 3:00 PM

0 · Reply

PepsiLover Jul. 27 at 3:11 PM

$IKT This stock is so stable even with routine P&D every few months lol, really wish this one gonna work out next year.

0 · Reply

Avocado_smash Jul. 27 at 12:37 PM

$IKT PT 2.68++

0 · Reply

LSOTradingDesk Jul. 26 at 9:13 AM

$IKT Worth watching for RSI to actually turn up through 40 before treating this as an entry zone — right now it's still in the falling phase of the pullback.

0 · Reply

BiotechJedi1728 Jul. 24 at 9:28 PM

$IKT Whoever sold 60,000 shares at 2.40 will be regretting that Monday.

1 · Reply

Goodguy22 Jul. 24 at 8:40 PM

Bought $IKT shares at 2.37

0 · Reply

Mjf04288 Jul. 24 at 8:01 PM

$IKT Dang!

0 · Reply

BiotechJedi1728 Jul. 24 at 2:56 PM

$IKT Feeling hella good so I am gonna keep on dancing !! 💃 🕺

0 · Reply

PepsiLover Jul. 23 at 7:48 PM

$IKT We breaking the cycle?

0 · Reply

Stock_Catcher Jul. 23 at 12:04 PM

$IKT Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

0 · Reply

GregK13 Jul. 20 at 12:18 AM

$IKT Pay attention to short interest here. It’s dropped massively!

2 · Reply

GregK13 Jul. 20 at 12:17 AM

$IKT This could easily bounce up hard on Monday morning opening for a great swing or day trade.

0 · Reply

PharmToBank Jul. 17 at 4:29 PM

$IKT I don't expect this will be a big catalyst as it was likely expected but it appears orphan drug designation was granted yesterday (not to be confused with FDA approved for orphan indication)

0 · Reply

BiotechJedi1728 Jul. 15 at 1:12 PM

$IKT $2 could be new floor. Maybe she is curling up. Consolidating for another move up I hope.

0 · Reply

topstockalerts Jul. 14 at 5:24 PM

$IKT if this holds, could get interesting fast

0 · Reply

Zardiw Jul. 14 at 4:43 PM

#DDAmanda Chart on $KUST. Your thoughts? Also scanning: $NVNI $IKT $SHPH See more DDAmanda finds: https://DDAmanda.com/

0 · Reply

topstockalerts Jul. 14 at 2:56 PM

$IKT the stock is behaving with a lot of confidence today.

1 · Reply

HOLY__GRAIL Jul. 14 at 2:10 PM

$IKT 2.15 is next before lunch. 2.32 by close.

0 · Reply

Market Cap	326.12M
Revenue (ttm)	0.00
Net Income (ttm)	-48.26M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	580,800
Avg Vol	876,156
Day's Range	N/A - N/A
Shares Out	132.03M
Stochastic %K	84%
Beta	0.95
Analysts	Strong Sell
Price Target	$6.00